Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Genzyme’s Lemtrada Approved in Argentina for Treatment of Multiple Sclerosis
Direct demonstration of elevated aldehyde dehydrogenase in human hematopoietic progenitor cells.
[Optical coherence tomography in multiple sclerosis].
High dose naltrexone for dyskinesias induced by levodopa.
A Study to Evaluate the Long-term Safety, Tolerability and Effect of Daily Oral Laquinimod 0.6 mg on Disease Course in Subjects With Relapsing Multiple Sclerosis
Recurrent Nicolau syndrome associated with subcutaneous glatiramer acetate injection-a case report.
Laquinimod reduces neuroaxonal injury through inhibiting microglial activation.
Multiple sclerosis and breast cancer.
Severe haematological complications during treatment with natalizumab.
MS and NMO: Partners No More.
Benign Multiple Sclerosis: Does it exist?
Endogenous retroviruses and multiple sclerosis--new pieces to the puzzle.
Improvement of internuclear ophthalmoparesis in multiple sclerosis with dalfampridine.
Dispositional optimism is unidimensional or bidimensional? The Portuguese revised Life Orientation Test.
Ophthalmic Evaluations in Clinical Studies of Fingolimod (FTY720) in Multiple Sclerosis.
Separated at birth? The functional and molecular divergence of OLIG1 and OLIG2.
Paediatric acquired demyelinating syndromes: incidence, clinical and magnetic resonance imaging features.
The OSCAR-IB Consensus Criteria for Retinal OCT Quality Assessment.
UPDATE 2-FDA panel supports approval of Sanofi's MS drug Lemtrada
Cytotoxic NKG2C+ CD4 T Cells Target Oligodendrocytes in Multiple Sclerosis.
Solitary sclerosis: Progressive neurological deficit from a spatially isolated demyelinating lesion: A further report.
Dynamic walking features and improved walking performance in multiple sclerosis patients treated with fampridine (4-aminopyridine).
Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor.
Patient page. Multiple sclerosis and vitamin D.
Imaging Microglial/Macrophage Activation in Spinal Cords of Experimental Autoimmune Encephalomyelitis Rats by Positron Emission Tomography Using the Mitochondrial 18 kDa Translocator Protein Radioligand [18F]DPA-714.
Pages
« first
‹ previous
…
147
148
149
150
151
152
153
154
155
…
next ›
last »